Concord Biotech block deals, bulk deals, insider trading and stake changes
NSE: CONCORDBIOBSE: 543960Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,375.30.
28 Oct: open ₹1,319.90, high ₹1,333.00, low ₹1,262.60
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,271 Cr496th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 46.98
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,80,22234.2% delivered
Concord Biotech's insiders have 16 trade disclosures on record, the latest on 2 Feb 2025. Its promoter group made no purchase or sale on the market in the 12 months to 28 Oct 2026.
Concord Biotech insider trading
The company's own latest disclosure on record is from Sep 2024.Insider trading, all companies
Sep 2024
- PRAKASH SAJNANI₹0.05 Cr200 sharesSold or invoked · Designated Person · 24 Sep 2024 · disclosed 2 Feb 2025
- PRAKASH SAJNANI₹0.25 Cr1,000 sharesSold or invoked · Designated Person · 20 Sep 2024 · disclosed 2 Feb 2025
- PRAKASH SAJNANI₹0.11 Cr500 sharesSold or invoked · Designated Person · 19 Sep 2024 · disclosed 2 Feb 2025
- PRAKASH SAJNANI₹0.32 Cr1,500 sharesSold or invoked · Designated Person · 18 Sep 2024 · disclosed 2 Feb 2025
- PRAKASH SAJNANI₹0.21 Cr1,000 sharesSold or invoked · Designated Person · 17 Sep 2024 · disclosed 2 Feb 2025
- Prakash Lalchand Sajnani₹1.08 Cr5,000 sharesSold · 16 Sep 2024 · disclosed 23 Sep · stake 0.02% before, 0.02% after
- Chandrashekhar Mukundrao Chawan₹0.21 Cr1,000 sharesSold · 16 Sep 2024 · disclosed 23 Sep · stake 0.01% before, 0.01% after
- Devang Bhatt₹0.52 Cr3,000 sharesSold · 2 Sep 2024 · stake 0.01% before, 0.01% after
Jun 2024
- Kanishka Kapoor₹14 Cr10,000 sharesSold · Immediate relative · 12 Jun 2024 · disclosed 13 Jun · held 10,000 before
- Ravi Kapoor10,000sharesGave · Director · 4 Jun 2024 · Gift · stake 0.21% before, 0.20% after
Feb 2024
- Rajendra Modi₹0.60 Cr4,000 sharesSold · 26 Feb 2024 · disclosed 27 Feb · stake 0.02% before, 0.02% after
- Raksha Modi₹0.30 Cr2,000 sharesSold · Immediate relative · 26 Feb 2024 · disclosed 27 Feb · stake 0.02% before, 0.02% after
- Raksha Modi₹0.29 Cr2,000 sharesSold · Immediate relative · 23 Feb 2024 · disclosed 24 Feb · stake 0.02% before, 0.02% after
- Mr. Chandrashekhar Mukundrao Chawan₹0.14 Cr1,000 sharesSold · 23 Feb 2024 · disclosed 24 Feb · stake 0.01% before, 0.01% after
Nov 2023
- UTPAL SHETH₹0.03 Cr253 sharesBought · Other · 20 Nov 2023 · disclosed 22 Nov · held 1,468 before, holds 1,721 after
- UTPAL SHETH₹0.19 Cr1,468 sharesBought · Other · 13 Nov 2023 · disclosed 20 Nov · holds 1,468 after
Trades by the company's promoters, directors, key managers, employees and their relatives, as each disclosed them. Value is what the filer stated; the mode is shown where the shares moved off the market.
Concord Biotech stake sales and purchases
All 2 disclosures on record.
May 2024
- Sold1575773 Ontario Inc3.39% of the company35,48,211 sharesholds 2.00% after28 May 2024 · filed under the 2% rule · Open Market
Aug 2023
- AcquiredEstate of Late Mr. Rakesh Jhunjhunwala along with pacholds 24.80% after18 Aug 2023 · filed under the 5% rule
The 5% rule: an investor discloses on reaching 5% of the company. The 2% rule: a holder of 5% or more discloses each change of 2% or more, including one that takes it below 5%. A transfer exempt from an open offer, the offer to buy from every other shareholder that a large purchase otherwise brings, is disclosed too. Each line shows what its filing states, which can be a smaller change than its rule names.
Concord Biotech block deals and bulk deals
Last 12 months, since 29 Oct 2025: 4 bulk deals, ₹256 Cr bought and ₹369 Cr sold Bought and sold in deals. Each deal's shares times its price, added up for the buyers and apart for the sellers, so a block deal, which names both, counts on each side.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Monday 31 Aug 20262 firms · ₹181 Cr bought · ₹294 Cr soldNet sold ₹113 Cr
- Sold1575773 ONTARIO INCSold 20,92,325 at ₹1,404.102.00% of the company₹294 Cr
- BoughtDSP MUTUAL FUNDBought 12,88,114 at ₹1,404.101.23% of the company₹181 Cr
Wednesday 25 Feb 20261 firm · ₹75 Cr bought · ₹75 Cr soldNet sold ₹0.04 Cr
- Both waysNK SECURITIES RESEARCH PRIVATE LIMITEDBought 6,16,952 at ₹1,217.94Sold 6,16,952 at ₹1,218.580.59% of the companyNet nil₹75 Cr bought
Friday 20 Sep 20243 firms · ₹331 Cr bought · ₹192 Cr soldNet bought ₹139 Cr
- SoldUBS PRINCIPAL CAPITAL ASIA LIMITEDSold 7,40,159 at ₹2,589.860.71% of the company₹192 Cr
- BoughtTHE VANGUARD GROUP INC A/C VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUNDBought 6,97,936 at ₹2,596.080.67% of the company₹181 Cr
- BoughtTHE VANGUARD GROUP INC A/C VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VANGUARD INTERNATBought 5,77,183 at ₹2,596.080.55% of the company₹150 Cr
Tuesday 28 May 20242 firms · ₹83 Cr bought · ₹483 Cr soldNet sold ₹400 Cr
- Sold1575773 ONTARIO INCSold 35,48,211 at ₹1,361.263.39% of the company₹483 Cr
- BoughtNORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBALBought 6,00,000 at ₹1,386.950.57% of the company₹83 Cr
Thursday 25 Jan 20242 firms · ₹22 Cr bought · ₹22 Cr soldNet nil
- SoldBNP PARIBAS ARBITRAGEBlock dealSold 1,53,421 at ₹1,421.700.15% of the company₹22 Cr
- BoughtSOCIETE GENERALEBlock dealBought 1,53,421 at ₹1,421.700.15% of the company₹22 Cr
Friday 18 Aug 20233 firms · ₹255 Cr bought · ₹174 Cr soldNet bought ₹81 Cr
- BoughtNORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBALBought 8,99,037 at ₹900.05₹81 Cr
- Both waysNK SECURITIES RESEARCH PRIVATE LIMITEDBought 11,31,896 at ₹930.12Sold 11,31,896 at ₹930.55Net nil₹105 Cr bought
- Both waysGRAVITON RESEARCH CAPITAL LLPBought 7,35,455 at ₹935.17Sold 7,35,455 at ₹935.55Net nil₹69 Cr bought
A bulk deal is one client trading more than half a per cent of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 15 deals on record since listing on 18 Aug 2023.